Mouse Anti-Mouse PD-1 (CD279) (Clone 384-35) – Recombinant in vivo Functional Grade

Mouse Anti-Mouse PD-1 (CD279) (Clone 384-35) – Recombinant in vivo Functional Grade

Product No.: P710

- -
- -
Product No.P710
Clone
384-35
Target
PD-1
Product Type
Recombinant Monoclonal Antibody
Alternate Names
Programmed Death-1, CD279, PD1, PDCD1
Isotype
Mouse IgG1
Applications
B
,
FA
,
in vivo

- -
- -
Select Product Size

Data

Administration of mAb 384-35 shows tumor volume more than 2.5 fold smaller compared to RMP1-14
Administration of mAb 384-35 significantly increases survival past 100 days compared to RMP1-14
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Mouse
FC Effector Activity
Active
Recommended Isotype Controls
Immunogen
Mouse PD-1
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<1.0 EU/µg
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
2-8°C Wet Ice
Additional Applications Reported In Literature ?
B,
FA,
in vivo,
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Anti-PD1 antibody (clone 384-35) recognizes an epitope on mouse PD-1.
Background
This anti-PD1 antibody was generated by immunizing PD-1-/- mice with mouse PD-1. The resulting antibody is fully murinized and contains no sequences from other species.

PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
Antigen Distribution
PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.
Ligand/Receptor
PD-L1 (B7-H1), PD-L2
PubMed
NCBI Gene Bank ID
UniProt.org
Q02242
Research Area
Apoptosis
.
Cancer
.
Cell Biology
.
Cell Death
.
Immunology
.
Inhibitory Molecules
.
Tumor Suppressors

References & Citations

1. Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117.
2. Honjo, T. et al. (1992) EMBO J. 11:3887.

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.